Key facts
- It has raised $22.5M; the latest was Later Stage VC ($10.0M) in Jun 2024.
- Notable investors include Impact Assets, Innovation Authority, Catalytic Impact Foundation, Exerte Partners, ADEC Private Equity Investments — 17 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 17 names
- ·Watchlist + deal alerts for OCON Therapeutics
- ·The full record, as it builds
Funding rounds
No funding rounds for OCON Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About OCON Therapeutics
Developer of an intrauterine drug-delivery technology designed for the treatment of uterus-based conditions. The company's product is made from a super-elastic alloy and is an ideal carrier for multiple drugs to the uterus to treat a variety of conditions such as abnormal uterine bleeding (AUB), heavy menstrual bleeding (HMS), myomas or fibroids, and infertility, providing clinicians with technology to improve and impact women's health and quality of life.
- Sector
- Healthcare
- HQ
- Modiin, Israel
- Founded
- 2011
- Employees
- 37
- Website
- oconmed.com/
- Ownership
- Privately Held (backing)
OCON Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in OCON Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on OCON Therapeutics in its N-PORT filings yet. We sweep new filings monthly.